Antibody Drug Conjugates Market Insights 2018-2023 and Forecast to 2033 - Top 10 Players Dominate with 99.26% Share; Roche Leads with 36.24%, Followed by Daiichi Sankyo Company, and Seagen Inc.
July 12, 2024 06:37 ET
|
Research and Markets
Dublin, July 12, 2024 (GLOBE NEWSWIRE) -- The "Antibody Drug Conjugates Global Market Opportunities and Strategies to 2033" report has been added to ResearchAndMarkets.com's offering.The global...
The State of the Biopharmaceutical Industry 2024 Edition (Mid-Year Update): Anti-Obesity Medications Take Center Stage
July 03, 2024 04:06 ET
|
Research and Markets
Dublin, July 03, 2024 (GLOBE NEWSWIRE) -- The "State of the Biopharmaceutical Industry 2024 Edition (Mid-Year Update)" report has been added to ResearchAndMarkets.com's offering.Although the...
Middle East & Africa Antibody Drug Conjugates Market Forecast to 2030 - Growing Strategic Partnerships to Develop Antibody Drug Conjugates and Escalating Pipeline of ADCs
June 26, 2024 04:23 ET
|
Research and Markets
Dublin, June 26, 2024 (GLOBE NEWSWIRE) -- The "Middle East & Africa Antibody Drug Conjugates Market Forecast to 2030 - Regional Analysis - By Technology, Application, and Distribution Channel"...
Europe Antibody Drug Conjugates Market Forecast to 2030: Increasing Investments to Develop ADCs Fuels the European Antibody Drug Conjugates Market
June 07, 2024 03:47 ET
|
Research and Markets
Dublin, June 07, 2024 (GLOBE NEWSWIRE) -- The "Europe Antibody Drug Conjugates Market Forecast to 2030 - Regional Analysis - By Technology, Application, and Distribution Channel" report has been...
ADC Therapeutics Makes Grants to New Employees Under Inducement Plan
June 03, 2024 16:05 ET
|
ADC Therapeutics SA
LAUSANNE, Switzerland, June 03, 2024 (GLOBE NEWSWIRE) -- ADC Therapeutics SA (NYSE: ADCT) today announced that the Company has made grants of options to purchase an aggregate of 109,800 of the...
ADC Therapeutics to Participate in the Jefferies Global Healthcare Conference
May 30, 2024 07:15 ET
|
ADC Therapeutics SA
LAUSANNE, Switzerland, May 30, 2024 (GLOBE NEWSWIRE) -- ADC Therapeutics SA (NYSE: ADCT) today announced that Ameet Mallik, Chief Executive Officer, will present a company overview at the Jefferies...
Antibody Drug Conjugates (ADC) Size, Share & Trends Analysis Report 2024: Global Market to Surpass $24 Billion by 2030, Driven by a Strong Product Pipeline & Rising Incidence and Prevalence Of Cancer
May 13, 2024 10:22 ET
|
Research and Markets
Dublin, May 13, 2024 (GLOBE NEWSWIRE) -- The "Antibody Drug Conjugates Market Size, Share & Trends Analysis Report By Application (Blood Cancer, Breast Cancer), By Technology (Type-cleavable,...
ADC Therapeutics to Participate in 2024 RBC Capital Markets Global Healthcare Conference
May 09, 2024 07:15 ET
|
ADC Therapeutics SA
LAUSANNE, Switzerland, May 09, 2024 (GLOBE NEWSWIRE) -- ADC Therapeutics SA (NYSE: ADCT) today announced that Ameet Mallik, Chief Executive Officer, will participate in a fireside chat at the 2024...
Antibody-Drug Conjugates (ADC) Industry Overview 2024: Market to Exceed $40 Billion by 2029, Driven by Daiichi Sankyo's Enhertu, Roche's Kadcyla, Astellas Pharma, Pfizer's Padcev, & Gilead's Trodelvy
April 26, 2024 06:59 ET
|
Research and Markets
Dublin, April 26, 2024 (GLOBE NEWSWIRE) -- The "Antibody-Drug Conjugates (ADC): Market Overview" report has been added to ResearchAndMarkets.com's offering. The global ADC market grew from $50...
FibroGen Announces Clinical Data from Dose Escalation Phase 1b Study of FG-3246 (FOR46) in Combination with Enzalutamide in Patients with Metastatic Castration Resistant Prostate Cancer will be Presented at the 2024 American Society of Clinical Oncology Annual Meeting
April 24, 2024 16:02 ET
|
FibroGen, Inc.
SAN FRANCISCO, April 24, 2024 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced that clinical data from the dose escalation portion of the Phase 1b/2 study of FG-3246 in combination...